Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00617734 · ClinicalTrials.gov registry record · Phase 2
Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 97
- Enrollment target
NCT00617734 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 97 participants.
The verdict
NCT00617734, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 97 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if IMC-A12 alone or in combination with Cetuximab (Erbitux®) can increase the time prior to disease progression in participants with Squamous Cell Head and Neck Cancer who have had disease progression and platinum-containing chemotherapeutic regimen.
Interventions
- BIOLOGICAL IMC-A12 (cixutumumab)
- BIOLOGICAL cetuximab (Erbitux ®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2008-03 |
| Est. Completion | 2012-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00617734
The ClinicalTrials.gov registry entry for NCT00617734 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which IMC-A12 (cixutumumab) is the first listed.
NCT00617734 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00617734 about?
NCT00617734 is a clinical study titled "Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck". The purpose of this study is to determine if IMC-A12 alone or in combination with Cetuximab (Erbitux®) can increase the time prior to disease progression in participants with Squamous Cell Head and Neck Cancer who have had disease progression and platinum-containing chemotherapeutic regimen.
What is the current status of trial NCT00617734?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 97 participants. The study started on 2008-03. Estimated completion is 2012-07.
What interventions are being tested in trial NCT00617734?
The interventions under investigation include: IMC-A12 (cixutumumab) (BIOLOGICAL), cetuximab (Erbitux ®) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00617734?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.